Rahul Banerjee: Why CAR-T recipients may appear to be at increased SPM risk?

Rahul Banerjee shared a post by The Cancer Letter on X, adding:

“Thanks The Cancer Letter for the chance to comment on excellent work by Kai Rejeski, Miguel Perales, Roni Shouval, et al in Clinical Cancer Research. Many theories we’ve postulated for why CAR-T recipients may appear to be at increased SPM risk – now we have data to back this up!”

Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

Authors: Tobias Tix, Mohammad Alhomoud, Roni Shouval, Edward R. Scheffer Cliff, Miguel-Angel Perales, David M. Cordas dos Santos, and Kai Rejeski.

Quoting The Cancer Letter:

“Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows.”

Source: The Cancer Letter/X and Rahul Banerjee/X

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco.   He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.